Stockreport

It Looks Like C4 Therapeutics, Inc.'s (NASDAQ:CCCC) CEO May Expect Their Salary To Be Put Under The Microscope [Yahoo! Finance]

C4 Therapeutics, Inc.  (CCCC) 
NASDAQ:AMEX Investor Relations: ir.chinacache.com
PDF Total compensation is similar to the industry average C4 Therapeutics' three-year loss to shareholders was 87% while its EPS was down 2.9% over the past three years [Read more]